Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Non-Small Cell Lung Cancer Clinical Trials

Review the non-small cell lung cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 524

TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
KK-LC-1 TCR T Cells for the Treatment of Metastatic Gastric, Lung, Breast, and Cervical Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Status: Active
Location: 2 locations
A Study of DM001 in Patients With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adagrasib in Combination with Olaparib for the Treatment of KRAS G12C Mutated Advanced Solid Tumors with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of ZN-c3 in Participants With Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients with Stage IA Lung Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Dabrafenib and/or Trametinib Rollover Study
Status: Active
Location: 2 locations
Evaluating the Impact of Treatment Timing on Effectiveness of Immunotherapy Treatment in Patients with Advanced or Metastatic Non-small Cell Lung Cancer or other Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York